Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma
Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.
CAR T-cells Rapidly Evolving as Cancer Therapies
Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.
Dr. Susan O'Brien on Next-Generation Small Molecules in CLL
March 20th 2016Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).
Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer
Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.
Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma
March 20th 2016John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.
Dr. Terri Woodard on Preservative Measures for Women With Ovarian Cancer
March 20th 2016Terri Woodard, MD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses if conservative management for women with ovarian cancer is warranted.
Extended Phase III Data Illuminates Ibrutinib Survival Benefit in CLL
Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.
Potential of Immuno-Oncology Continues to Expand
Immuno-oncology has advanced rapidly, with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. As these agents rush through development, several questions remain regarding the optimal patients for treatment and the next steps for further improving outcomes.
Dr. Jennifer Brown on RESONATE 2 Trial in CLL
Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses RESONATE 2 and frontline ibrutinib use in patients with chronic lymphocytic leukemia (CLL).
Dr. Michael Williams on Lenalidomide Plus Rituximab in First- Line MCL
March 19th 2016Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).
Dr. Sagar Lonial on Early Treatment Versus Observation for Smoldering Multiple Myeloma
March 18th 2016Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.
Kareem Abdul-Jabbar Discusses Living With CML
March 18th 2016Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemia‎ (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.
Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL
Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Frontline Therapy Rapidly Evolving for Multiple Myeloma
March 18th 2016Shaji Kumar, MD, discusses how the phase III SWOG S0777 study, which investigated the combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, significantly changed the frontline treatment paradigm for patients with multiple myeloma
Mittendorf Explains What's New With NeuVax in Breast Cancer
March 14th 2016Elizabeth A. Mittendorf, MD, PhD, discusses nelipepimut-S (NeuVax), a peptide derived from HER2 protein combined with granulocyte-macrophage colonystimulating factor that is currently being investigated as a single-agent, in combination with standard-of-care therapies, and in multiple settings and subtypes of breast cancer.
